AMGEN INC. |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 299.6 USD | -3.74% |
|
+8.41% | +4.02% |
| 12:17pm | North American Morning Briefing : Stock Futures -2- | DJ |
| 03/05 | News Highlights : Top Company News of the Day - Friday at 5 PM ET | DJ |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
Amgen Inc. is one of the world's leading biotechnology groups. Net sales break down by source of revenue as follows:
- drug sales (94.2%): drugs for treating cancer, metabolic disorders, bone diseases, renal failure, hemophilia, etc.;
- other (5.8%): primarily royalties.
The United States account for 70.3% of net sales.
Sector
Pharmaceuticals
Calendar
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
30
Last Close Price
311.3
USD
Average target price
313.3
USD
Spread / Average Target
+0.65%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +4.02% | 167B | |
| +31.11% | 662B | |
| +21.96% | 546B | |
| -5.27% | 359B | |
| +17.01% | 323B | |
| +4.69% | 289B | |
| +13.68% | 234B | |
| +3.81% | 198B | |
| -10.63% | 194B | |
| -2.21% | 157B |
- Stock Market
- Equities
- AMGN Stock
- News Amgen Inc.
- Amgen : 'Underappreciated' Inflammation Portfolio Set to Trigger Growth, RBC Capital Analyst Says